The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905).
Anne S. Tsao
No relevant relationships to disclose
James Moon
No relevant relationships to disclose
Ignacio Ivan Wistuba
No relevant relationships to disclose
Nicholas J. Vogelzang
No relevant relationships to disclose
Gregory Peter Kalemkerian
No relevant relationships to disclose
Mary Weber Redman
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose